R OU ND TABLE
EXPERT TALK
Pharma Focus Asia Patient-centric Drug Delivery Contract manufacturing leaders offer their insight into drug delivery innovation and development. Lonnie Barish, VP, Business development and marketing, Bora John Ross, President, Metrics Marc Brown, Chief Scientific Officer and Co-founder, MedPharm
What’s on the horizon for patientcentric drug delivery?
As more of the world reports better access to healthcare, the demand for safe effective therapeutics of all kinds will continue to escalate. This broad global acceptance of pharmaceutical based healthcare has accelerated the development of more sophisticated medications to treat the unmet needs of an increasing number of patients. Conventionally, the market for all pharmaceuticals has been dominated by North America, followed closely by Europe. However, with an increasingly ageing population and growing spending on healthcare per capita, demand for pharmaceuticals in the entire AsiaPacific region is expected to see rapid, significant growth for the foreseeable future.11 Asia Times reported in 2019 that the market for pharmaceuticals in China was set to reach US$161 billion, taking a 1. http://www.pharmabiz.com/NewsDetails. aspx?aid=121681&sid=21
64
P H A RM A F O C U S A S I A
ISSUE 41 - 2020
30 per cent share of the global market. During the 2019 World Innovators Meet, Fu Xudong, senior vice-president of Bristol-Myers Squibb noted that China has emerged as world’s second-largest pharmaceutical market, following the United States.2 Dose delivery in development
Oral Solid Dose (OSD) formulations continue to lead the market as a preferred dosage form. According to the US FDA Center for Drug Evaluation and Research (CDER), of the 38 small molecule drugs approved by the agency in 2019, 26 (68 per cent) were OSDs (19 tablets and 7 capsules).3 Demand for topical pharmaceuticals, another growing and patient centric drug delivery modality, is projected to reach US$129.8 billion by 2025 from US$95.2 billion in 2020, at a 2. https://asiatimes.com/2019/12/chinas-pharma-marketpoised-to-hit-us161-billion/ 3 https://www.fda.gov/about-fda/fda-organization/centerdrug-evaluation-and-research-cder
compound annual growth rate of 6.4 per cent during the forecast period. MarketsandMarkets points out that growth in this market is being driven by the increasing prevalence of skin and soft tissue infections, eye diseases emergency treatments for burns.4 Pharmaceutical development and innovation is coming from both drug developers and their contract manufacturing partners. Pharma is relying more and more on external partners to deliver the solutions they need to deliver their formulations and explore the new modalities, personalised genetic therapeutics and chemistries being introduced. To gain better insight into drug dose delivery technology trends Pharma Focus Asia invited leadership from three contract development and manufacturing organisations (CDMOs) serving the Asia-Pacific market for their input and perspectives on what is on the horizon for drug delivery. 4 https://www.marketsandmarkets.com/PressReleases/ topical-drug-delivery.asp
